{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-233427","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2025-10-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.249941+00:00","generated_at":"2026-05-17T04:27:55.350542+00:00","sec_items":["3.01","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Adicet Bio granted 180-day Nasdaq extension; transferred to Capital Market","bullets":["Extension until April 6, 2026 to regain $1.00 minimum bid price; transferred to Nasdaq Capital Market effective Oct 9, 2025.","Company may consider reverse stock split to meet bid price requirement; if not regained, Nasdaq will issue delisting notice.","Previous 180-day compliance period ended Oct 6, 2025; extension granted Oct 7, 2025.","No immediate impact on common stock listing; ACET continues trading under symbol ACET."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-233427","json":"https://secwatch.observer/filing/0001193125-25-233427.json","markdown":"https://secwatch.observer/filing/0001193125-25-233427.md","text":"https://secwatch.observer/filing/0001193125-25-233427.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000119312525233427/0001193125-25-233427-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000119312525233427/acet-20251007.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:27:55.350542+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a16a099b7102d8204337539302f805eed28f16c1","claim":"Adicet Bio, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"October 7, 2025, the Company received a notice (the Extension Notice) from Nasdaq informing the Company that Nasdaq has granted the Company an additional 180 calendar days, or until April 6, 2026, to regain compliance with the Bid Price Requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In connection with the Extension Notice, the listing of the Common Stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective at the opening of business on October 9, 2025. The Extension Notice has no other immediate effect o","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720580/000119312525233427/0001193125-25-233427-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001213900-26-055912","ticker":"ISPC","company_name":"iSpecimen Inc.","filed_at":"2026-05-13T21:00:25+00:00","headline":"iSpecimen prices $2.5M private placement at $5.12/share; regains Nasdaq minimum bid price compliance","event_type":"other_material","sec_items":["1.01","3.01","3.02","7.01","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-055912","json":"https://secwatch.observer/filing/0001213900-26-055912.json","markdown":"https://secwatch.observer/filing/0001213900-26-055912.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026055912/0001213900-26-055912-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026055912/ea0290143-8k_ispecimen.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"October 7, 2025, the Company received a notice (the Extension Notice) from Nasdaq informing the Company that Nasdaq has granted the Company an additional 180 calendar days, or until April 6, 2026, to regain compliance with the Bid Price Requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In connection with the Extension Notice, the listing of the Common Stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective at the opening of business on October 9, 2025. The Extension Notice has no other immediate effect o","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1720580/000119312525233427/0001193125-25-233427-index.htm","comparable_excerpt":"minimum $1.00 per share required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum\nBid Price Requirement”) for the prior 30 consecutive business days. On May 12, 2026","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026055912/0001213900-26-055912-index.htm"}},{"accession":"0001213900-26-060662","ticker":"TNON","company_name":"Tenon Medical, Inc.","filed_at":"2026-05-22T21:15:15+00:00","headline":"Tenon Medical receives Nasdaq delisting notice for failing minimum stockholders' equity","event_type":"other_material","sec_items":["3.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-060662","json":"https://secwatch.observer/filing/0001213900-26-060662.json","markdown":"https://secwatch.observer/filing/0001213900-26-060662.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1560293/000121390026060662/0001213900-26-060662-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1560293/000121390026060662/ea0291962-8k_tenon.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"October 7, 2025, the Company received a notice (the Extension Notice) from Nasdaq informing the Company that Nasdaq has granted the Company an additional 180 calendar days, or until April 6, 2026, to regain compliance with the Bid Price Requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In connection with the Extension Notice, the listing of the Common Stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective at the opening of business on October 9, 2025. The Extension Notice has no other immediate effect o","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1720580/000119312525233427/0001193125-25-233427-index.htm","comparable_excerpt":"May 21, 2026, Tenon Medical, Inc. (the “Company”)\nreceived a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated May 21, 2026, notifying\nthe Company that it is no longer in compliance with the","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1560293/000121390026060662/0001213900-26-060662-index.htm"}},{"accession":"0001104659-26-057974","ticker":"HUMA","company_name":"Humacyte, Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Humacyte receives Nasdaq deficiency notice for bid price below $1.00; 180 days to comply","event_type":"other_material","sec_items":["3.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057974","json":"https://secwatch.observer/filing/0001104659-26-057974.json","markdown":"https://secwatch.observer/filing/0001104659-26-057974.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818382/000110465926057974/0001104659-26-057974-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818382/000110465926057974/tm2614071d1_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"October 7, 2025, the Company received a notice (the Extension Notice) from Nasdaq informing the Company that Nasdaq has granted the Company an additional 180 calendar days, or until April 6, 2026, to regain compliance with the Bid Price Requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In connection with the Extension Notice, the listing of the Common Stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective at the opening of business on October 9, 2025. The Extension Notice has no other immediate effect o","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1720580/000119312525233427/0001193125-25-233427-index.htm","comparable_excerpt":"May 4, 2026, Humacyte, Inc. (the “Company”)\nreceived a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification\nthat, for the 30 consecutive business days ended May 1, 2026, th","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1818382/000110465926057974/0001104659-26-057974-index.htm"}},{"accession":"0001213900-26-059270","ticker":"XXI","company_name":"Twenty One Capital, Inc.","filed_at":"2026-05-20T12:49:08+00:00","headline":"Tether International acquires SoftBank's stake in Twenty One Capital; board members resign","event_type":"other_material","sec_items":["1.02","3.01","5.02","8.01","9.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 8.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-059270","json":"https://secwatch.observer/filing/0001213900-26-059270.json","markdown":"https://secwatch.observer/filing/0001213900-26-059270.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2070457/000121390026059270/0001213900-26-059270-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2070457/000121390026059270/ea0291071-8k_twenty.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"October 7, 2025, the Company received a notice (the Extension Notice) from Nasdaq informing the Company that Nasdaq has granted the Company an additional 180 calendar days, or until April 6, 2026, to regain compliance with the Bid Price Requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In connection with the Extension Notice, the listing of the Common Stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective at the opening of business on October 9, 2025. The Extension Notice has no other immediate effect o","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1720580/000119312525233427/0001193125-25-233427-index.htm","comparable_excerpt":"o independent directors, the minimum number required during the transition period\nfor compliance with Section 303A.07(a) of the NYSE Listed Company Manual, as provided in Section 303A.00 of the NYSE Listed Company Manual","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2070457/000121390026059270/0001213900-26-059270-index.htm"}},{"accession":"0001437749-26-016538","ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2026-05-13T12:03:45+00:00","headline":"Reviva Pharmaceuticals to be delisted from Nasdaq May 14, 2026; will trade on OTCQB","event_type":"other_material","sec_items":["3.01","8.01"],"materiality_score":1.0,"calibrated_materiality_score":1.0,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 8.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-016538","json":"https://secwatch.observer/filing/0001437749-26-016538.json","markdown":"https://secwatch.observer/filing/0001437749-26-016538.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926016538/0001437749-26-016538-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926016538/rvph20260512_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"October 7, 2025, the Company received a notice (the Extension Notice) from Nasdaq informing the Company that Nasdaq has granted the Company an additional 180 calendar days, or until April 6, 2026, to regain compliance with the Bid Price Requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In connection with the Extension Notice, the listing of the Common Stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective at the opening of business on October 9, 2025. The Extension Notice has no other immediate effect o","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1720580/000119312525233427/0001193125-25-233427-index.htm","comparable_excerpt":"May 12, 2026 indicating that the Panel had determined to delist the Company’s common stock from Nasdaq. The Company’s common stock will be suspended from trading on Nasdaq as of the open of trading on May 14, 2026. Begin","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926016538/0001437749-26-016538-index.htm"}},{"accession":"0001493152-26-019078","ticker":"GNLN","company_name":"Greenlane Holdings, Inc.","filed_at":"2026-04-27T23:59:59+00:00","headline":"Greenlane regains Nasdaq compliance; BIC limits warrant conversion; board lock-up to April 2027","event_type":"other_material","sec_items":["3.01","7.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 8.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-019078","json":"https://secwatch.observer/filing/0001493152-26-019078.json","markdown":"https://secwatch.observer/filing/0001493152-26-019078.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743745/000149315226019078/0001493152-26-019078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743745/000149315226019078/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"October 7, 2025, the Company received a notice (the Extension Notice) from Nasdaq informing the Company that Nasdaq has granted the Company an additional 180 calendar days, or until April 6, 2026, to regain compliance with the Bid Price Requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In connection with the Extension Notice, the listing of the Common Stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective at the opening of business on October 9, 2025. The Extension Notice has no other immediate effect o","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1720580/000119312525233427/0001193125-25-233427-index.htm","comparable_excerpt":"March 25, 2026, Greenlane Holdings, Inc. (the “ Company ”) received a written notice\n(the “ Notice ”) from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market LLC (“ Nasdaq ”)\nindicating that Nasdaq s","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1743745/000149315226019078/0001493152-26-019078-index.htm"}},{"accession":"0001213900-26-062844","ticker":"ADTX","company_name":"Aditxt, Inc.","filed_at":"2026-05-29T20:21:24+00:00","headline":"Aditxt receives Nasdaq deficiency for negative equity; delisting hearing set for June 11","event_type":"other_material","sec_items":["3.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062844","json":"https://secwatch.observer/filing/0001213900-26-062844.json","markdown":"https://secwatch.observer/filing/0001213900-26-062844.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1726711/000121390026062844/0001213900-26-062844-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1726711/000121390026062844/ea0292786-8k_aditxt.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"October 7, 2025, the Company received a notice (the Extension Notice) from Nasdaq informing the Company that Nasdaq has granted the Company an additional 180 calendar days, or until April 6, 2026, to regain compliance with the Bid Price Requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In connection with the Extension Notice, the listing of the Common Stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective at the opening of business on October 9, 2025. The Extension Notice has no other immediate effect o","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1720580/000119312525233427/0001193125-25-233427-index.htm","comparable_excerpt":"May 27, 2026, Aditxt, Inc. (the “Company”)\nreceived a letter (the “Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market\nLLC (“Nasdaq”) notifying the Company that, based on the stockholders’ equity of $(35,174,386) reported in the Company’s\nQuarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”), the Company no longer satisfies the minimum\nstockholders’ equity requirement of $2,500,000 for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1)\n(the “Stockholders’ Equity Requirement”). The Letter further","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1726711/000121390026062844/0001213900-26-062844-index.htm"}},{"accession":"0001104659-26-066974","ticker":"LIMN","company_name":"Liminatus Pharma, Inc.","filed_at":"2026-05-27T20:30:41+00:00","headline":"Liminatus Pharma receives Nasdaq delisting notice; appeals filed","event_type":"other_material","sec_items":["3.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-066974","json":"https://secwatch.observer/filing/0001104659-26-066974.json","markdown":"https://secwatch.observer/filing/0001104659-26-066974.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926066974/0001104659-26-066974-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926066974/tm2615785d1_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"October 7, 2025, the Company received a notice (the Extension Notice) from Nasdaq informing the Company that Nasdaq has granted the Company an additional 180 calendar days, or until April 6, 2026, to regain compliance with the Bid Price Requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In connection with the Extension Notice, the listing of the Common Stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective at the opening of business on October 9, 2025. The Extension Notice has no other immediate effect o","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1720580/000119312525233427/0001193125-25-233427-index.htm","comparable_excerpt":"May 20, 2026, the Company received a notice\nfrom Nasdaq stating that the Company had not regained compliance with the MVLS Rule and the MVPHS Rule. Accordingly, its securities will\nbe delisted from The Nasdaq Global Mark","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926066974/0001104659-26-066974-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}